Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023

Euro Surveill. 2024 Jan;29(1):2300703. doi: 10.2807/1560-7917.ES.2024.29.1.2300703.

Abstract

We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults ≥ 60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95% CI: 66.6-74.3), VE against ICU admission was 73.3% (95% CI: 42.2-87.6).

Keywords: COVID-19; COVID-19 vaccination; Vaccine effectiveness.

MeSH terms

  • Adult
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Critical Care
  • Hospitalization
  • Humans
  • Netherlands / epidemiology
  • Vaccine Efficacy
  • Vaccines*

Substances

  • COVID-19 Vaccines
  • Vaccines